Absci's Stock Surge#
Absci Corp (NASDAQ:ABSI) saw its shares jump by 22.2%, reaching $4.815 in early trading. This increase comes in response to encouraging news in the hair-loss treatment market.
Market Potential for Hair-Loss Treatments#
The surge in Absci's stock was influenced by KeyBanc, which pointed out that positive results from a competitor, Veradermics (NASDAQ:MANE), regarding its oral hair-loss pill suggest that the hair-loss market is large enough to support various treatments. KeyBanc estimates that the market for hair-loss therapies could exceed $40 billion.
Absci's Experimental Drug#
KeyBanc also highlighted Absci’s experimental hair-growth drug, ABS-201. They believe that this drug could work alongside existing treatments rather than compete with them, as it requires only two to three injections over six months, making it a potentially convenient option for patients.
Renewed Interest in Hair-Loss Therapies#
Interest in hair-loss treatments has been revitalized following Nektar Therapeutics’ recent announcement about its experimental injection, which has shown promise in stimulating hair regrowth for patients with alopecia areata, a condition characterized by patchy hair loss. This renewed focus on hair-loss solutions may further boost the market's growth.